Panel Discussion: Strategizing Your Preclinical Program to Remove Obstacles for Your Phase Zero or FIH Trial

• Using early biodistribution and dosimetry to guide safe, effective dosing for phase zero/fih trials
• Confirming target specificity preclinically to reduce off-target risks and strengthen your IND package
• Aligning radiochemistry with GMP standards early to avoid delays and ensure clinical readiness

Speakers:

Jessica Guarnaschelli

Independent Consultant

JNG International

Andrew Li

Senior Director, Business Development

C Ray Therapeutics

Sean Carlin

VP Translational Sciences

Abdera Therapeutics

Melissa Rodnick

Program Manager

Sirtex Medical Limited

Jean-Luc Vanderheyden

Head

ONCIDIUM-FOUNDATION